Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews

WANG Xue; YUAN Peng; YUE Jian; SI Yiran; HU Nanlin; ZHENG Fangchao; JIANG Peidi

doi:10.3971/j.issn.1000-8578.2020.19.1554

WANG Xue, YUAN Peng, YUE Jian, SI Yiran, HU Nanlin, ZHENG Fangchao, JIANG Peidi. Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 427-431. DOI: 10.3971/j.issn.1000-8578.2020.19.1554

Citation:

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews

Graphical Abstract

Graphical Abstract

Abstract

Abstract

Objective To observe the toxicities of immune checkpoint inhibitors.
Methods We retrospectively analyzed the clinical data of 20 advanced tumor patients who received immune checkpoint inhibitors therapy in Cancer Hospital of Chinese Academy of Medical Sciences from March 2017 to August 2019, and collected the immune-related adverse events.
Results The median immunotherapy time was 4.0 months. The immune-related adverse events occurred in 6 patients: one case of grade Ⅰ gastroenteritis, one case of grade Ⅰ dermatitis, one case of grade Ⅰ thyroiditis, one case of grade Ⅲ hepatitis, one case of grade Ⅲ pneumonia and one case of grade Ⅳ pneumonia; the median time of occurrence was 5.3 months.
Conclusion As the incidence of immune-related adverse events is relatively high and sometimes life-threatening, it is crucial for early recognition, accurate diagnosis and prompt intervention of the toxicities associated with immune checkpoint inhibitors.

FullText(HTML)

References (19)

Cited By

Turn off MathJax

Article Contents

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews

Graphical Abstract

Abstract

Catalog

Export File

Citation

Format

Content